Vasculitis & polymyalgia rheumatica
Upadacitinib for refractory Behcet’s syndrome: a multi-centre, single-arm trial
Authors' conclusion
Upadacitinib represents a potential therapeutic option for patients with refractory BS.
Study context
- Population
- Patients with BD refractory to at least two immunosuppressive agents or one targeted therapy for at least 6 months16 male
- Participants
- 27 patients
- Outcome
- Overall response rate (CR plus PR)
- Follow-up
- 24 weeks
Methodological detailsmulticentre, Conducted from February 2023 to August 2025
- Multicentre
- Conducted from February 2023 to August 2025
Main finding
As reported in the abstract
ORR (CR plus PR)
Overall response rate (ORR) at 24 weeks
85.2%
23/27
CRs
16
PRs
7
Further findings
Median BDCAF scores, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and GC dosage · week 24
- Significant reductions by week 24
Median CRP and ESR among the 23 patients in remission at week 24 · up to 48 weeks
- Significantly lower at 48 weeks than at 24 weeks
CR by system involvement · 24 weeks
- Cardiovascular involvement
- 3 (100.0%)
- Ocular symptoms
- 5 (83.3%)
- Gastrointestinal involvement
- 10 (76.9%)
- Mucocutaneous symptoms
- 16 (59.3%)
- Articular involvement
- 1 (16.7%)
Relapse during follow-up
- Patients with relapse
- 3
Safety
- No serious adverse events reported
Original publication
Upadacitinib for refractory Behcet’s syndrome: a multi-centre, single-arm trial. Arthritis Res Ther. Published 3 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →